Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC
- PMID: 23023514
- DOI: 10.1002/ijc.27881
Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC
Abstract
Collapsin response mediator protein-2 (CRMP-2) is the first described and most studied member of a family of proteins that mediate the addition of tubulin dimers to the growing microtubule. CRMPs have mainly been studied in the nervous system, but recently, they have been described in other tissues where they participate in vesicle transport, migration and mitosis. In this work, we aimed at studying the role of CRMP-2 in lung cancer cell division. We first explored the expression of CRMP-2 and phosphorylated (Thr 514) CRMP-2 in 91 samples obtained from patients with localized nonsmall cell lung cancer. We observed a significant correlation between high levels of nuclear phosphorylated CRMP-2 and poor prognosis in those patients. Interestingly, this association was only positive for untreated patients. To provide a mechanistic explanation to these findings, we used in vitro models to analyze the role of CRMP-2 and its phosphorylated forms in cell division. Thus, we observed by confocal microscopy and immunoprecipitation assays that CRMP-2 differentially colocalizes with the mitotic spindle during cell division. The use of phosphodefective or phosphomimetic mutants of CRMP-2 allowed us to prove that anomalies in the phosphorylation status of CRMP-2 result in changes in the mitotic tempo, and increments in the number of multinucleated cells. Finally, here we demonstrate that CRMP-2 phosphorylation impairment, or silencing induces p53 expression and promotes apoptosis through caspase 3 activation. These results pointed to CRMP-2 phosphorylation as a prognostic marker and potential new target to be explored in cancer therapy.
Copyright © 2012 UICC.
Similar articles
-
Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237. J Thorac Oncol. 2013. PMID: 23287853
-
Prognostic significance of TAZ expression in resected non-small cell lung cancer.J Thorac Oncol. 2012 May;7(5):799-807. doi: 10.1097/JTO.0b013e318248240b. J Thorac Oncol. 2012. PMID: 22481233
-
Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer.J Cancer Res Clin Oncol. 2016 Jan;142(1):263-72. doi: 10.1007/s00432-015-2040-0. Epub 2015 Aug 30. J Cancer Res Clin Oncol. 2016. PMID: 26319393
-
Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer.Lung Cancer. 2002 Jan;35(1):35-41. doi: 10.1016/s0169-5002(01)00287-2. Lung Cancer. 2002. PMID: 11750711 Review.
-
Collapsin response mediator protein-1: a novel invasion-suppressor gene.Clin Exp Metastasis. 2003;20(1):69-76. doi: 10.1023/a:1022598604565. Clin Exp Metastasis. 2003. PMID: 12650609 Review.
Cited by
-
Collapsin Response Mediator Protein-2 Ameliorates Sevoflurane-Mediated Neurocyte Injury by Targeting PI3K-mTOR-S6K Pathway.Med Sci Monit. 2018 Jul 18;24:4982-4991. doi: 10.12659/MSM.909056. Med Sci Monit. 2018. PMID: 30018280 Free PMC article.
-
Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.Cancer Sci. 2013 Dec;104(12):1586-92. doi: 10.1111/cas.12278. Epub 2013 Oct 21. Cancer Sci. 2013. PMID: 24011394 Free PMC article.
-
(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.Mol Neurobiol. 2016 Apr;53(3):1959-1976. doi: 10.1007/s12035-015-9141-2. Epub 2015 Apr 7. Mol Neurobiol. 2016. PMID: 25846820
-
Implication of Adipogenesis-Coupled CRMP2 Functional Profile in Metabolic Homeostasis and Imbalance.Biomedicines. 2022 Oct 17;10(10):2603. doi: 10.3390/biomedicines10102603. Biomedicines. 2022. PMID: 36289868 Free PMC article.
-
Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.Breast Cancer Res. 2013 Mar 18;15(2):R25. doi: 10.1186/bcr3403. Breast Cancer Res. 2013. PMID: 23506684 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous